[ad_1]
A potential HIV vaccine developed by Johnson & Johnson failed to provide protection against the virus in a mid-term study, the drugmaker said on Tuesday.
J&J plans to end this study, which involved young women from sub-Saharan Africa. But researchers will pursue a separate, late-stage trial involving a different composition of the vaccine in men and transgender people.
The study in sub-Saharan Africa looked at approximately 2,600 women considered to be at high risk of contracting HIV, which causes AIDS. Participants were randomly selected to receive either the vaccine or a placebo, and the researchers found that the vaccine was only 25% effective at preventing HIV.
A potential HIV vaccine developed by Johnson & Johnson failed to provide protection against the virus in a mid-term study, the drugmaker said on Tuesday.
(iStock)
MODERNA COVID-19 VACCINE DOUBLES ANTIBODY LEVELS COMPARED TO PFIZER SHOT: STUDY
“HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development due to its ability to attack, hijack and evade the human immune system,” said Dr. Paul Stoffels, Scientific Director of J&J , in a press release.
CLICK HERE TO GET THE FOX NEWS APP
J&J said his other study on the potential vaccine was being conducted in Europe and the Americas, where different strains of HIV are circulating.
Johnson & Johnson, based in New Brunswick and New Jersey, also makes one of three vaccines approved by U.S. regulators for the prevention of COVID-19. J&J is also developing vaccines against sepsis and respiratory syncytial virus.
[ad_2]
Source link